

## DAFTAR PUSTAKA

- American Cancer Society. (2016, Februari 16). *American Cancer Society*. Retrieved Juli 20, 2018, from <https://www.cancer.org/cancer/prostate-cancer.html>
- Bonci, D., & Maria, R. (2016). miR-15/miR-16 loss, miR-21 up-regulation, or deregulation of their target genes predict poor prognosis in prostate cancer patients. *Molecular & Cellular Oncology*, 2372-3556.
- Crossland, R. E., Norden, J., Bibby, L. A., Davis, J., & Dickinson, A. M. (2006). Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. *Journal of Immunological Methods*, 39-49.
- Daniswara Marsa H..(2018).Profil Ekspresi mRNA CXCR4 pada Karsinoma Kolorektal dengan Invasi Pembuluh Vaskular dan Limfatik di RSUP Dr. Sardjito.*skripsi*.Program Studi Pendidikan Dokter
- Gann, P. H. (2002). Risk Factors for Prostate Cancer. *Reviews in Urology*, IV(5), 53-60.
- Jeff, H., Lal, P., & Alex, S. (2004). Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance. *American Journal of Pathology*, 164(1), 217-227.
- Komite Penanggulangan kanker Nasional. (2017). Panduan Penatalaksanaan Kanker Prostat. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kotb, S., Mosharafa, A., Essawi, M., & Hassan, H. (2014). Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. *Tumor Biology*, I(1), 1-5.
- Kumar, V., Cotran, R. S., & Robbins, S. L. (2003). *Robbins Basic Pathology 10th Edition* (6th ed.). Philadelphia: Saunders.
- Kumarswamy, R., Ingo, V., & Thum, T. (2011). Regulation and function of miRNA-21 in health and disease. *RNA Biology*, VIII(5), 706-713.
- Lekchnov, E. A., Zaporozhchenko, I. A., Morozkin, E. S., Bryzgunova, O. E., Vlassov, V. V., & Laktionov, P. P. (2016). Protocol for miRNA isolation from biofluids. *Analytical Biochemistry*, 78-84.
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods*, 402-408.
- Mahn, R., Rogenhover, S., Heukamp, L. C., Ruecker, A. v., Muller, S. C., & Ellinger, J. (2011). Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer. *Basic and Translational Science*, 9-16.

- Markowska, A., Pendergrast, R. S., Pendergrast, J. S., & Pendergrast, P. S. (2017). A novel method for the isolation of extracellular vesicles and RNA from urine. *Journal of Circulating Biomarkers*, 1-7.
- National Collaborating Centre for Cancer. (2014). *Prostate Cancer : diagnosis and treatment* (Final ed.). Wales: National Collaborating Centre for Cancer.
- Pan, J., Ding, M., & Wu, K. (2017). Exosomes in diagnosis and therapy of prostate cancer. *Oncotarget*, VIII(57), 97693-97670.
- Patel, E. R., & Klein, E. A. (2009). Risk factors for prostate cancer. *Nature Clinical Practice Urology*, VI(2), 87-95.
- Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. *Signal Transduction and Targeted Therapy*, I(1), 1-9.
- Pfaffl, M. W. (2004). Quantification strategies in real-time PCR. *A-Z of quantitative PC*, 87-112.
- Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., . . . Lupold, S. E. (2009). miR-21: An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth. *Cancer*, XVIII(69), 7165-7169.
- Putra Richardus H. S..(2017).Profil Ekspresi *hsa-miR-19b-3p* pada Sampel Urin Pasien *Benign Prostatic Hyperplasia (BPH)* dan Kanker Prostat.*Tesis*.Program Studi Bioteknologi
- Schaefer, A., Jung, M., Miller, K., Lein, M., Kristiansen, G., Erbersdobler, A., & Jung, K. (2010). Suitable reference genes for relative quantification of miRNA. *Experimental and Molecular Medicine*, 749-758.
- Sharma, N., & Baruah, M. M. (2018). The microRNA signatures:aberrantly expressed miRNAs in prostate cancer. *Clinical and Translational Oncology*, I(1), 1-19.
- Shtam, T. A., Roman, K. A., & Elena, V. Y. (2013). Exosomes are natural carriers of exogenous siRNA to human cells. *Cell Communicating & Signaling*, I(1), 1-10.
- Steward, B., & Wild, C. (2014). *World Cancer Report 2014*. Lyon: World Health Organization.
- Valentino, A., Reclusa, P., Sirera, R., Giallombardo, M., Camps, C., Pauwels, P., . . . Rolfo, C. (2017). Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. *Clinical & Translational Oncology*, I(1), 651-657.
- Vinay, K., Abbas, A. K., & Aster, J. C. (2013). *Robbins Basic Pathology* (9th ed.). Canada: Elsevier.

- Vlachos, I. S., Kostoulas, N., Vergoulis, T., Georgakilas, G., Reczko, M., Maragkakis, M., . . . Hatzigeorgiou, A. G. (2012). DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. *Nucleic Acids Research*, 498-504.
- Yang, Y., Guo, J.-X., & SHao, Z.-Q. (2017). miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. *Asian Pacific Journal of Tropical Medicine*, 87-91.
- Zedan, A. H., Hansen, T. F., & Madsen, J. S. (2018). microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cance. *Tumor Biology*, I(1), 1.
- Zhang, H.-L., Yang, L.-F., Zhu, Y., Yao, X.-D., Zhang, S.-L., Dai, B., . . . Ye, D.-W. (2011). Serum miRNA-21:Elevated Levels in Patients With Metastatic Hormone-Refractory Prostate Cancer and Potencial Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy. *The Prostate*, I(71), 326-331.
- Zhao, H., Ma, T.-F., Liu, L.-L., Sun, W.-J., Guo, L.-X., Wang, S.-Q., . . . Zhang, Y.-P. (2018). *Identification of valid reference genes for mRNA and microRNA normalisation in prostate cancer cell lines*. Kunming: Springer Nature.